Pages

Subscribe:

Friday, May 15, 2015

DOES STEM-CELL THERAPY WORK FOR ANIMALS?

Retiree Paul Jaynes was heartbroken when his 9-year-old Labrador, Cookie, suddenly stopped walking last year. The once-athletic dog struggled to stand and, if she moved at all, collapsed after a few steps.

He carried his 90-pound companion to his truck, drove her to the vet and braced himself for the bad news. Surely she couldn’t live like this.

Instead, his veterinarian told him about a newly available procedure involving stem cells. In a single day, the vet said, they could remove the cells from Cookie’s fatty tissues, process them and re-inject them into her joints. She could go home immediately.

“It was very dramatic,” Jaynes says. “The day after surgery, she was standing. She was hesitant, but she was standing and walking a little. I thought: ‘Are you kidding me?’ Within a week, she was almost back to her old self.”

That was last September, and six months later Cookie is still going strong, Jaynes says. While he has no doubts about the treatment, some veterinarians worry that marketing of stem-cell therapy for animals has gotten ahead of the scientific research needed to validate its use.

The results, while sometimes promising, are not universal.

“Most of what you hear is anecdotal – ‘Oh, I tried this, and it helped my dog,'” says Dr. Jeffrey Peck, a veterinary surgeon at Affiliated Veterinary Specialists, based in Maitland, Fla. “This has grown in its marketing exponentially greater than it has grown in evidence.”

Much of his practice is in orthopedics – typically, dogs with hip dysplasia or arthritis. He tried using stem-cell therapy with his patients in 2008 but dropped it after a dozen cases in which he saw no improvement.

“I don’t refuse to do it if a client really wants to try, but I give them my disclaimer,” he says. “I tell them: ‘I don’t think I’m going to hurt anything. But I doubt I’m going to help anything either.'”

At $1,400 to $3,000 for the procedure, most pet owners opt out, he says.

But Peck acknowledges that some of his colleagues are decidedly more optimistic about the therapy, and some have treated their own pets with stem cells with varying degrees of success.

Dr. Janis Fullenwider, veterinarian and owner of an area animal hospital, began offering the treatment there about a year ago, though she has only treated five dogs so far.

“I think it will turn out to be extremely promising – not just for osteoarthritis but for all kinds of things,” she says. “I’m actually banking some stem cells from my own dogs now.”

Her enthusiasm comes despite an early – and profound – disappointment. Four years ago, one of her dogs was a subject in a pilot study to test stem-cell therapy for cardiomyopathy in Dobermans, half of whom eventually develop the fatal heart-muscle disease. Only 15 Dobermans were enrolled, and Fullenwider’s dog died the day after the treatment.

Though the dog might have died that day regardless, ultimately researchers said the stem cells showed no sign of helping.

But those results only underscore the need for more studies, Fullenwider says, and they don’t dissuade her from using the therapy for osteoarthritis. Of the dogs treated at her practice, she says, all showed progress.

“I do think, because it’s such an (emerging) therapy, a lot of people don’t yet understand it,” she adds. “And it’s still expensive right now.”

But the price is starting to drop, and the research is rapidly growing. The University of Florida, for instance, is currently enrolling subjects for an ongoing study of stem-cell therapy in dogs with arthritic elbows (the middle joint of the front legs).

Fourteen have already completed the six-month trial, during which the owners, other veterinarians and technicians are kept in the dark about which dogs are getting the therapy and which are getting a placebo. The placebo dogs get the treatment at the end.

“I think for this application – for arthritis – it’s very useful, says Dr. Anna Dunlap, a veterinarian and orthopedic fellow working on the study. “The owners tend to guess correctly. They’ll come in at three months and say, ‘I think my dog is in the stem-cell group because he’s really improving’ – and they’re usually right.”

Her research uses stem cells from umbilical cords harvested during canine cesarean-section births. But the more common practice currently is to surgically remove them from fatty tissue – either behind the dog’s neck or on its abdomen – process the cells, and then inject them into the troublesome site. Though adverse effects are rare, the procedure does bring a risk of joint infection.

The therapy, proponents say, reduces inflammation, speeds healing and may even help to regenerate tissue – the most controversial claim.

And some vets are using stem cells to treat horses, dogs and, less often, cats for a wide variety of ailments.

“We use the therapy for degenerative joint disease, but we also use it for what’s called compassionate-use cases, which simply means that they don’t have enough research yet to claim that stem-cell therapy works for it,” says Erica Kent, director of operations for Newman Veterinary Centers in Central Florida, one of the first to offer the therapy. “That includes kidney disease, irritable-bowel disease, stomatitis – which is a gum disease in cats … I actually treated my own cat for irritable-bowel disease.”

She also treated her basset-hound mix for arthritis. In both cases, she says, she witnessed dramatic progress.

But for Carol Hall’s 15-year-old Shiba Inu mix, Ginger, the response was less impressive.

“I really didn’t see an improvement,” says Hall, an area resident. “I think sometimes she had a little more pep, but I think her arthritis was just too advanced.”

Ginger underwent knee-replacement surgery in 2012, but Hall sought the stem-cell therapy last year in hopes of easing the dog’s overall pain and increasing her mobility. And while Hall can’t detect much difference, she doesn’t regret the $1,500 decision.

“I did research it – because I would never let her go into surgery at age 14 if I didn’t think it would help,” she says. “And I’m sure it helped in other ways that I can’t see. After all, her life expectancy is 9 years, and she’s still going at 15.”

source : http://goo.gl/m3Fh8o

Sunday, March 22, 2015

जांघ के मांस से बना दिया महिला का स्तन

दिल्ली के डॉक्टरों ने चमत्कारिक काम करते हुए रविवार को एक 23 वर्षीय लड़की की जांघों का अतरिक्त मांस निकालकर प्रयोगशाला में प्राकृतिक स्तन का निर्माण कर दिया। गौरतलब है कि पोलैंड सिंड्रोम के एक आनुवांशिक विकार के चलते इस लड़की के बाएं स्तन का पूर्ण विकास नहीं हो पाया था। 

मध्यप्रदेश के इंदौर जिले की रहने वाली इस लड़की का इलाज दिल्ली के सर गंगाराम अस्पताल में किया गया। डॉक्टरों ने बताया कि लड़की इस विकार के चलते अवसाद में थी और हीनभावना से ग्रसित रहती थी। लेकिन इस लड़की ने हिम्मत नहीं हारी और इंटरनेट पर इसका समाधान खोजने की कोशिश की। डॉक्टरों ने बताया कि वह स्तन प्रत्यारोपड और ग्राफ्टिंग प्रक्रिया से भी गुजर सकती थी।

सर गंगा राम अस्पताल के प्लास्टिक और कॉस्मेटिक सर्जन विवेक कुमार से सलाह लेने के बाद इस लड़की ने फैट ग्राफ्टिंग प्रक्रिया से गुजरना उचित समझा क्योंकि उसने पाया कि यह प्रक्रिया प्राकृतिक है और यह बेहद आसानी सी सर्जरी है। 

कुमार ने बताया कि स्तन विकास के लिए यह आधुनिक तकनीक है और यह भारत में हाल ही में चर्चा में आई है। उन्होंने बताया कि स्तन की कॉस्मेटिक और पुनर्निर्माण संबंधी अन्य प्रक्रियाओं में भी इसका इस्तेमाल किया जाता है।

Thursday, March 19, 2015

IVF Nutrients May Influence Gender Selection In Embyros, But Is It Safe?

Chinese scientists believe that certain undisclosed nutrients given to embryos during in vitro fertilization may favor the development of male fetuses over female. The study is significant because it could possibly lead to a new technique for gender selection. However, experts are more concerned about what other changes that aren’t as obvious as sex these gender-specific nutrients may bring about.
During IVF a woman is stimulated to produce more eggs, which are then collected and fertilized outside of her body. For around five days fertilized embryos are grown in a petri dish, where lab technicians will then choose the healthiest looking embryos to reintroduce into the body for pregnancy.

Closely Guarded Nutrients

As reported in New Scientist, technicians working on IVF with cows found that the type of culture medium, or nutrients that embryos were grown in could influence how well male and female embryos develop. The 2001 study also revealed that a glucose-rich medium seemed to favor the development of male embryos and the loss of females in cows.
In order to test if the same remained true for human embryos, scientists at Peking University Third Hospital in China analyzed more than 4,400 IVF procedures during 2011 and 2013. The team took note of the type of culture medium used to grow each embryo. Although the specific components of the medium were kept confidential, the team revealed that in one medium the proportion of male births was 56 percent, while for another the proportion was just 45 percent. The uneven proportions remained even when the researchers took other factors into context, such as the parent’s age, body mass, and the type of infertility they were experiencing. Based on these findings, the team concluded that, like the bovine fetuses, human fetuses also varied in their response to different culture mediums depending on their gender.

Legalities

Gender selection is legal in the United States, but a 2014 survey given by the American Society for Reproductive Medicine revealed that only 21 percent of the American public actually agreed with the practice of choosing gender based only on sex preference with no medical underlying. Also known as gender selection or family balancing, certain techniques can nearly guarantee the birth of a certain sex. However, Slate reported that the American Society for Reproductive Medicine has expressed concern that otherwise healthy women are undergoing unnecessary medical treatments for the sole purpose of gender selection.
“It’s very commonly done,” Dr. David Adamson, a board certified reproductive endocrinologist and surgeon working for the Advanced Reproductive Care fertility clinic in California, told Medical Daily. “The decision that I made not to do that, personally, is not shared by the majority of doctors. I have partners that I respect a lot who will do it. It’s a difficult issue.”
New Scientist also reported that gender selection in IVF is illegal in Canada, the UK, and other Western countries, but this technique presented in the Chinese study could possibly present a loophole. Anti-gender bias laws rule that technicians are not allowed to select embryos based on their gender, but fertility clinics are free to use whichever medium to grow the embryos. That is, if the procedure works — something that experts are still very skeptical of.
“I don’t think it's effective enough to say that it’s a good therapeutic intervention,” Adamson said. “This may well be true, but in the absence of information about the culture medium, it’s difficult to interpret.”
Daniel Brison, a consultant embryologist at the University of Manchester in the UK seemed to agree with Adamson’s reasoning.
"A couple reading this paper who have already got a girl might well say 'hmm, perhaps I should be using the [male-favoring] medium,'" Brison told New Scientist. "But it's not really a very effective method of choosing a gender."

Is It Safe?

Other than the ineffectiveness of the procedure, Adamson raised a far more troubling concern: safety. The period immediately following fertilization is known to be genetically critical, but the culture medium also affects embryo growth. As a study from Maastricht University Medical Center in the Netherlands found last year, culture medium could affect birth weight in babies — a factor tied to lifelong health factors, such as a weak heart and diabetes, New Scientist reported. It’s unknown what other changes adjusting this medium to favor certain genders may result in.
Adamson explained that there is “zero evidence” that such a change would have no other impact other than gender on the embryo. His opinion mounts against many studies that suggest it may. Furthermore, testing necessary to document what effects manipulating the culture media would have on an embryo would be completely unethical.

Thursday, March 12, 2015

Limited Self-Renewal Of Stem Cells In The Brain

Stem cells in the brain can produce neurons and are consequently seen as a hope for treatment. A team of researchers from the Helmholtz Zentrum München and Ludwig-Maximilians-Universität München (LMU) has now discovered that the self-renewal rate of the stem cells is however limited, explaining why their number drops over the course of a lifetime. This work now sets the basis for further investigation of the signalling pathways that maintain the stem cells. The results have been published in the journalNature Neuroscience.

The generation of neurons (neurogenesis) in humans is predominantly limited to development; in the adult stage it takes place in only a few regions of the brain. These regions contain neural stem cells that generate neurons in a process with various intermediary stages.
Stem cell renewal is limited – total number drops
Until now it was thought that maintaining the stem cell pool was based on the self-renewal of individual stem cells. The team of scientists headed by Dr. Jovica Ninkovic and Professor Dr. Magdalena Götz were able to refute this: Both the self-renewal rate and the diversity of neurons formed from the stem cells are limited, and the number of stem cells decreases with age.
"Our findings explain why neurogenesis declines in later years, as there are fewer and fewer neural stem cells. At the same time, we gained new knowledge on basic mechanisms of neurogenesis that until now were not understood," says first author Dr. Filippo Calzolari.
Therapeutic approaches must focus on stem cells themselves
Approaches to new therapies for brain diseases, such as stroke or dementia, for example, particularly concentrate on replacing lost neurons by stimulating the generation of new cells from stem cells. "In light of the fact that the stem cell supply is limited, we must now also look for ways to promote the self-renewal rate of the stem cells themselves and maintain the supply for a longer time," emphasizes Götz, Director of the Institute for Stem Cell Research at the Helmholtz Zentrum München and Chair of the Institute of Physiological Genomics at LMU.

Saturday, February 28, 2015

Stem Cell Therapy For Atrophic AMD Well Tolerated When Delivered Safely

Cell therapy with CNTO 2476, an adult stem cell treatment for atrophic age-related macular degeneration, is well tolerated when delivered safely into the subretinal space, a speaker told colleagues at Angiogenesis, Exudation, and Degeneration 2015.

Of the 35 subjects with bilateral geographic atrophy enrolled in the study, 33 received the cells via microcatheter.

“In this study, we need to do a better job with surgical delivery,” Allen C. Ho, MD, said, considering there was a 15% rate of retinal detachment with the method used. No patient had immune response, endophthalmitis, uveitis or tumor formation, however.

Ho gave early efficacy results on visual acuity accrued in the phase 1/2a clinical trial, but “with caution,” because the trial was small, unmasked and not controlled.

Mean visual acuity over 1 year in treated eyes improved four to five letters, whereas fellow eyes that were untreated lost approximately two letters, according to the presentation.

About 25% of treated eyes gained three lines of vision or more in best corrected visual acuity over 1 year, whereas no untreated eyes improved by that measure.

The strategy for therapy in this trial and in future trials of this cell line is to harvest adult umbilical tissue-derived cells without differentiation and to inject them subretinally to support or repair the diseased cells with cytokines or cell-to-cell interaction, according to the presentation.

“All the cells for this trial and the future trials will be derived from a single umbilical cord,” Ho said, with the cells being expanded according to good tissue practices, quality tested and cryopreserved into aliquots for delivery into the study subject’s eye.

A phase 2b randomized controlled trial is planned to begin in 2016, with an enrollment goal of 160 patients, Ho said – by Patricia Nale, ELS

Friday, February 27, 2015

Supreme Court asks government to explain stance on commercial surrogacy

PIL objects to India continuing to permit the practice while many others have banned it The Supreme Court yesterday asked the government to clarify its stand on commercial surrogacy, a thriving industry in the country, after a public interest litigation objected to the country continuing to permit the practice while many other countries have banned it. 

"...some countries like South Korea have banned it. We need to look into the larger issues involved in the petition," Justices Ranjan Gogoi and NV Ramana said, seeking explanation on the issue from ministries of health, commerce and external affairs, within four weeks. The Medical Council of India ( MCI) and the Indian Council of Medical Research (ICMR) also have been told to come up with their stands on the issue. 

The court was acting on a PIL that challenged commercial surrogacy, which has several deleterious effects on the physical and psychological health of the surrogate mothers, as violation of public policy and unethical. 

In commercial surrogacy, a woman, a third party rents out her womb for a price to a married couple. Their embryo is transplanted into her womb to grow. But she has no legal rights over the baby. 

Several countries now permit the surrogate mother to be part of the child's life. But in India, it is not allowed. 

Low medical costs also make India an attractive destination for married couples seeking surrogate mothers for their children. 

The PIL, filed by an advocate Jayashree Wad, said a large number of foreign couples have of late started coming to India to use Indian women as surrogates. 

Senior advocate Shekhar Naphade said this has be come a flourishing business for doctors and hospitals in the country. 

Most surrogates are women from poorer sections, he said, adding that there's the issue of exploitation of their vulnerabilities by the affluent class, comprising doctors, hospitals and institutions that carry on such business. 

"This amounts to violation of the rights under Article 21 (right to life and liberty). Neither the Parliament nor state legislatures have prohibited this practice," he said, urging the court to intervene to end this unethical practice. 

Naphade also claimed that the ministry of commerce and industry had to facilitate such surrogacy permitted imports of human embryos into the country. "...human embryo is human life in the miniature form and permit .. 

Tuesday, February 24, 2015

STEM CELLS FROM YOUR TEETH COULD REPAIR YOUR EYES

Stem cells from the dental pulp of wisdom teeth can be coaxed to turn into cells of the eye’s cornea.

Researchers say this could one day be used to repair corneal scarring due to infection or injury. This could also be new source of corneal transplant tissue made from the patient’s own cells.

Corneal blindness, which affects millions of people worldwide, is typically treated with transplants of donor corneas, says senior investigator James Funderburgh, professor of ophthalmology at the University of Pittsburgh School of Medicine.

“Shortages of donor corneas and rejection of donor tissue do occur, which can result in permanent vision loss,” Funderburgh says. “Our work is promising because using the patient’s own cells for treatment could help us avoid these problems.”

Experiments showed that stem cells of the dental pulp, obtained from routine human third molar, or wisdom tooth, could be turned into corneal stromal cells called keratocytes, which have the same embryonic origin.

The researchers injected the engineered keratocytes into the corneas of healthy mice, where they integrated without signs of rejection. They also used the cells to develop constructs of corneal stroma akin to natural tissue.

“Other research has shown that dental pulp stem cells can be used to make neural, bone, and other cells,” says lead author Fatima Syed-Picard, also of the university’s ophthalmology department. “They have great potential for use in regenerative therapies.”

In future work, the researchers will assess whether the technique can correct corneal scarring in an animal model.

The journal STEM CELLS Translational Medicine published the results.

The National Institutes of Health grants, Research to Prevent Blindness, and the Eye and Ear Foundation of Pittsburgh funded the work.


Source : http://goo.gl/ZGPtbq

Thursday, February 12, 2015

Cell Therapy For Atrophic AMD Well Tolerated When Delivered Safely

MIAMI — Cell therapy with CNTO 2476, an adult stem cell treatment for atrophic age-related macular degeneration, is well tolerated when delivered safely into the subretinal space, a speaker told colleagues at Angiogenesis, Exudation, and Degeneration 2015.
Of the 35 subjects with bilateral geographic atrophy enrolled in the study, 33 received the cells via microcatheter.

“In this study, we need to do a better job with surgical delivery,” Allen C. Ho, MD, said, considering there was a 15% rate of retinal detachment with the method used. No patient had immune response, endophthalmitis, uveitis or tumor formation, however.

Ho gave early efficacy results on visual acuity accrued in the phase 1/2a clinical trial, but “with caution,” because the trial was small, unmasked and not controlled.

Mean visual acuity over 1 year in treated eyes improved four to five letters, whereas fellow eyes that were untreated lost approximately two letters, according to the presentation.

About 25% of treated eyes gained three lines of vision or more in best corrected visual acuity over 1 year, whereas no untreated eyes improved by that measure.

The strategy for therapy in this trial and in future trials of this cell line is to harvest adult umbilical tissue-derived cells without differentiation and to inject them subretinally to support or repair the diseased cells with cytokines or cell-to-cell interaction, according to the presentation.

“All the cells for this trial and the future trials will be derived from a single umbilical cord,” Ho said, with the cells being expanded according to good tissue practices, quality tested and cryopreserved into aliquots for delivery into the study subject’s eye.

A phase 2b randomized controlled trial is planned to begin in 2016, with an enrollment goal of 160 patients, Ho said – by Patricia Nale, ELS




Source by : http://goo.gl/e23o5u

Wednesday, January 14, 2015

Stem cell therapy to cure hip arthritis; KGMU Docs Launch Pilot Project


When 26-year-old housewife Sudha started experiencing radiating pain from groin to thigh, she first dismissed it as an outcome of over-exertion and fatigue. The pain, however, increased to the extent that painkillers ceased to give any relief. After being examined, she was diagnosed with avascular necrosis (death of cells) in the right hip, one of the leading causes of hip arthritis.

She had no option but to live with the pain until she opted for stem cell treatment which is being offered at King George's Medical University on a pilot basis. Doctors in the orthopaedic department started using autologous stem cells to regenerate the hip bone a year ago and the effort has given extremely promising results. Their work has been published in the current edition of medical journal called Advances in Orthopaedics.

It may be noted that 16,000 new cases of avascular necrosis are reported each year in India and at least 100 cases come to KGMU. "We took up the most difficult cases of avascular necrosis wherein the cause of cellular death is not known," Dr Ajai Singh, who along with a senior professor R N Srivastava developed the procedure, told TOI.

Known as idiopathic avascular necrosis, this problem usually occurs in younger people and involves both limbs. Also, since the cause is not known, doctors work only to control the symptom which is like a compromise with the disease. As a result, the patient's life is controlled by pain killers that come with several side effects. The final option is to hold a joint replacement surgery which is not recommended in younger patients globally as chances of revision surgery are extremely high.

The patients and attendant families are apprised about the 45-minutes long procedure. It involves extraction of patient's bone-marrow to prepare autologous stem cells (generated from one's bone marrow) and place it over the affected bones under general anaesthesia. The patient is allowed to go home on the fifth day and kept under regular follow-ups. "Preliminary results showed over 50% reduction in pain at the time of discharge and estimated 25% reduction in necrotic area in three month," said Dr Singh who has kept track of all patients in the study.

The beneficiaries vouch for the outcomes. "I had to make a choice between restricted painful life that would worsen each day or the risk of opting for a new procedure. I chose the second hoping for positive outcomes," said Sudha who was operated in December. Engineering student Pawan shared, "Sometimes I felt I would turn into a person with disability. Now, I am sure of a fairly normal life."





source by : http://goo.gl/N5kVs2

Friday, January 9, 2015

How Does a Sperm Bank Work


With the introduction of IVF, surrogacy and other scientific options for reproduction, a sperm bank is no longer a taboo concept in society. Most of us still are not clear about the exact procedure entitled to a this bank. A detailed prospectus has been discussed in the following.

A lot of cases of infertility have been resolved with scientific methods and the progress that gives us many options for a safe and possible pregnancy, when the natural and traditional methods for conceiving fail. We have come across terms like IVF (in vitro fertilization) and surrogacy, that is literally a womb for pregnancy. Along with these, sperm donation is also a term that is not rare and taboo anymore, which is an important tool in dealing with infertility cases. It has been recognized as an important aspect in the fields of gynecology and human science. In many cases of infertility and many other reasons (which will discussed below) a donated sperm has been used for reproduction.

A sperm bank also known as cryobank, is the place where samples of sperms are stored. These are regulated by the Human Fertilization and Embryology Authority. An advantage of this bank is that the client can ask for a specific genetic structure of the sperm, that they wish the child to have. You can have your call when it comes to choosing how the child should look. Some people also wish to register a known donor, or provide their own donor, which is also known as surrogate parenting. How is this achieved? What is the procedure of legally donating sperm and how does the bank work? All these facts and more have been compiled in the following segment of the article.

Sperm Donation

There are many reasons why people wish to donate sperm. One major reason is to help an infertile couple have a child. Some will donate sperm to keep it safe for the future in case the individual has a job that can risk his life and reproductive ability, like athletes and sportsmen, army and military professionals. These individuals store their sperm so that they can still have their own child in the future. Medical conditions like cancer, future surgeries like vasectomy can also be the reason why men donate sperms and keep them safe. Some other reasons may be financial obligations and responsibilities. Donated sperms also help singles and gay couples who want a child and who will have their own genes. And also for homosexual women who want children, with her own eggs and genes. It is found that 1 out of 8 couples who are infertile use a donor sperm to help conception.

Process of Sperm Donation

Not every one can donate sperms. Though the name may sound very simple, it is actually a long process to finally donate sperm and get it registered. Sperm is only collected from healthy men, after proper application, an appointment and a series of tests. The person willing to donate can contact the bank, most of the time the information can be found on-line. The criteria for donation is: age of 18-40 years, no family history of disease, must be able to provide complete details of family medical history, must be free from any health issues and disease, should be willing to bear with the commitment made to the donation program.

Once you register after meeting the criteria, you will go through the first round of the process. The individual is consulted with an obstetrician and upon agreement, the first sample of semen is collected. The donor may be advised to abstain from ejaculation for at least 48 hours before the first sample screening for the best quality of sperm. It is then put through tests, for healthy quantity of sperms in the sample, testing for HIV and other sexual diseases. This may typically take 2 to 3 months to complete tests and screening.

The collection of sperm sample can be done in the bank's laboratory, or it can also be collected through something known as 'Priority Male Overnight Collection Kit'. By this the donor can collect the sample at home, in specially made sterile containers that are shipped to them and after the sample collection they can ship it to the bank through Fed ex, which is prepaid and arranged for the donor.
Once the screening is complete, and it gives a positive remark, the donor is called again for the second visit, here he can be asked to sign an agreement of consent to the entire donation process. A series of health tests and check ups follow after this for a few months. Many samples of sperm are taken from the donor as these tests progress.
How is the Donated Sperm Stored

Once the sperm is collected, it is handed over to the lab technician. The sperm is frozen, as well as the cells and tissues in the sample. A special liquid may be used to keep the sperm healthy and free from damage during freezing and thawing. This process of freezing sperm is called cryopreservation. He then, stores the sample in special containers called vials, these are thin containers, are sealed and kept in extremely cold temperatures, in containers filled with liquid nitrogen vapor. The temperatures can vary from (-150° C) to (-196° C). The donated sample, is also checked after freezing and thawing, to meet quality standards, like the minimum count of sperm after thawing a sample must be 20 million active or motile sperms per millimeter.

Time Limit of the Stored Sperm

A sperm has no expiry date, as long as it is stored well in aptly controlled atmosphere, it can stay as long as it is stored well. There are reports of sperms being stored for 20 years, which have been used for conception successfully. The only difference between a fresh sperm and a stored sperm is that fresh sperm are alive inside the uterus for 2-5 days, while a thawed and frozen sperm will stay alive for 24 hours.

Using Donor Sperm

After consulting your doctor you can contact the sperm bank. You can choose from the list of banks all over, as the sperms can be shipped easily. You can discuss with the bank its costs and the donor profiles. Though all samples may not have photographs and names, you can still get all physical details and features. This helps people who want to match the offspring as closely to the father. So a specific search is done, to get a sample with characteristics resembling the recipient (father).

Fees and Costs

For the donors, there are no specific fees, there are only certain rules and regulations, every sperm bank has its own norms, so these rules differ, they may include educational qualifications, specific body weight and height, etc. The donor gets an average of anything between $75 to few hundred dollars for each sample of semen. These may vary with each bank. For the recipient too, the costs of purchasing sperm may vary with every bank.

Donor Identity in Sperm Donation

The donor can either provide full details or remain anonymous. If the person wishes to give full details, he can do so. He can also opt for something known as 'ID Consent', which will allow the future offspring to know the donor's name after the child attains legal age (18 years). Even if the donor chooses to withhold the name, he still has to give descriptive details of himself and his family to the bank. The recipients are entitled of these details. He can choose to stay alien to the recipient or the future child forever or as long as he desires. Later if he wishes to change to ID consent, that is also possible. The bank however, is not responsible to track the donor, and also does not guarantee that the donor will be found at any stage. Also there is no rule that forces the donor to meet the future offspring.

Sperm donation and purchasing is a safe method and, has a good success rate. It is a healthy procedure and has helped many couples share the joy of being parents. Understanding this procedure is equally important, so make sure you consider all aspects of this program when donating or even purchasing sperm.

Monday, January 5, 2015

Corneal Blindness: Stem Cells May Provide Alternative Cure

There could be an alternative to corneal transplantation to cure blindness, thanks to collaborative research findings by a research team from India and the US.

The animal studies conducted on the efficacy of using stem cells to treat scarring of whitening of cornea, the central dark portion of the eye, in curing blindness gave positive results, Sayan Basu, consultant corneal surgeon and scientist, LV Prasad Eye Institute (LEPEI), told newspersons on Thursday.

Basu is working along with James L Funderburgh, Professor of Ophthalmology at the University of Pittsburgh School of Medicine in a collaborative research project.

The results of the animal studies have been published on Thursday in the latest issue of the journal Science Translational Medicine. “We found that when the stem cells were applied to damaged corneas, they healed and became clear again within four weeks of treatment while those untreated remained clouded,” he said.
‘Long way’

However, there is still a long way to go. Phase I clinical studies involving 10 patients at LVPEI are currently underway and might take another six months to be completed.

“We still need to figure out whether the same set of desired results could be achieved in human patients and also the required dosage,” Funderburgh, speaking from the US through Skype said.
Second phase 

Phase II clinical trials will have to be conducted. If all goes well, patients might be in a position to gain from this innovation after about three years.

“But, once proved, it will help treating corneal blindness in most cases at nominal cost,” Basu said. At present, the cost of corneal replacement ranges from ₹50,000 to ₹1.5 lakh. There are nearly 1.40 lakh patients in the waiting lists to receive corneas for transplantation in the country now, he added.





Source by : http://goo.gl/Yqs6Cm

Scientists Create Artificial Human Sperm, Eggs From Stem Cells

Scientists from Cambridge University have created artificial human eggs and sperm for the first time, using human embryonic stem cells and skin cells.

While this process was previously achieved in rats, this is the first time it has been done with humans. The findings were published in the journal 'Cell.'

However, the end result was not working sperm and eggs, but so-called germ cells that could potentially mature to become viable for fertility.

“Germ cells are ‘immortal’ in the sense that they provide an enduring link between all generations, carrying genetic information from one generation to the next,” Azim Surani, professor of physiology and reproduction at the University of Cambridge, said in a press release.

In biology, when an egg is fertilized by sperm, it divides into a group of cells called a blastocyst, which then develops into a foetus or the placenta.

Some cells become stem cells, which can then develop into any cell in the body. Some of these will become germ cells, and will then become sperm or eggs.

The scientists identified a gene known as SOX17, which decides which cells become sperm and egg cells. They then harvested these cells by culturing human embryonic stem cells for five days.

However, this doesn’t mean that men and women can donate any cells instead of sperm and eggs when they visit a fertility clinic – but the scientists hope the experiment will shed more light on the study of human genetics.

The research also gives scientists another way to examine how the environment impacts genes, such as how behavioural factors – like smoking and what we eat – can activate or deactivate genes.

The study of how genes are affected by environmental factors is known as epigenetic, and scientists hope it will give them a better understanding of cancer and other age-related illnesses.

First Stem-Cell Therapy Approved For Medical Use In Europe

The first stem-cell therapy has been approved by European regulators in a major step forward for advanced medicine in Britain. The European Medicines Agency (EMA) has recommended Holoclar, a treatment in which a patient’s own healthy stem cells are used to grow new cells which are then transplanted into the eye.

It is a major step forward for stem-cell therapies which have so far being confined to the lab and clinical trials. Experts predicted advanced treatments will be available on the NHS within a few years.

“This is exciting both because there are no other treatments for this sort of damage to the eye and because this is the first example in which a ‘medicine’ based on stem cells has been approved for use in humans,” Professor Graham McGeown, Reader in Physiology, Centre for Experimental Medicine, Queen's University Belfast.

“Because the cells come from the patient themselves, there should be no worries that the body will reject them as can happen when using a transplant from another person.

“This treatment will only be allowed under carefully defined conditions, however, so that the outcomes can be carefully monitored to see if the treatment works and doesn’t have any unexpected side-effects.”

Stem cells can act as a repair system for the body.

Limbal stem cells are located in the eye at the border between the cornea – the clear front part of the eye - and the sclera – the white of the eye.
Physical or chemical burns can cause loss of these stem cells, resulting in limbal stem cell deficiency, LSCD, a condition that is estimated to affect about 3.3 out of 100,000 people in the European Union and around 650 people in Britain.

Symptoms include pain, sensitivity to light, inflammation, excessive blood vessel growth, clouding of the cornea, and eventually blindness.
In LSCD the limbal stem cells become so diminished that they eyes can no longer make new cells to repair damage.

The new treatment takes a small sample of the patients healthy cornea, removes the stem cells and grows them until there are sufficient numbers to put back into the eye. The cells themselves then repair the damage.

Moorfields Eye Hospital in London has successfully treated around 20 people with Holocar so far in trials.

Prof Chris Mason, from University College London, told the BBC: "This move would enable far more people to access it, you could now prescribe this."

The EMA decision to approve Holoclar will now be sent to the European Commission for market authorization. It will then be up to Nice to decide whether to approve the therapy for use on the NHS.

Dr Dusko Ilic, Reader in Stem Cell Science, King's College London, said: “The therapeutic approach on which Holoclar is based is relatively well established and it was just a question of when it would be approved by regulatory agencies.

“It has been performed in multiple academic institutions around the world, including the UK. I hope that Holoclar is not just an exception, and that many more cellular therapy products will see market in the next year.”

Holoclar, has been developed by the Italian pharmaceutical company Chiesi Farmaceutici S.p.A.

Enrica Alteri, Head of EMA’s Human Medicines Evaluation Division said the decision represented a ‘major step forward’ for stem cell therapies.




Source by : http://goo.gl/D4wySn